Prescribing information and adverse event reporting information can be found at the bottom of this page.
Gastroenterology
RINVOQ®
(upadacitinib)
UK-RNQG-220017. Date of preparation: July 2022
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on [email protected]